Recently, RainMed Medical Coronary Function Measurement System (hereinafter referred to as "RainMed caIMR") has successfully entered the special approval channel for innovative medical devices of NMPA, and has obtained the priority of NMPA certification. As the world's leading non-interventional microcirculation diagnosis system, the approval of caIMR fully reflects the international leadership of its technology and its superior clinical value.   The approval of the innovative application of caIMR will accelerate its commercialization, accelerate the opening of tens of billions of blue ocean market for microcirculation diagnosis, and lead the cardiovascular field into a new era of comprehensive assessment of myocardial functional ischemia. It also lays a key foundation for RainMed Medical to build a vascular interventional surgery robot covering the whole process of comprehensive diagnosis and treatment. Announcement of the review results of the special application for innovative medical devices   As a green channel for medical device approval, the special approval channel for innovative medical devices has a high approval threshold and a very low approval rate. Since the implementation of the approval process in 2014, only 170 products have been approved in China and the approval rate is only 20%. Among them, the caIMR and caFFR of RainMed and their supporting supplies have been successfully approved to enter the green channel of innovative medical devices, demonstrating RainMed Medical's excellent innovative R&D capabilities.   Preferential policy support and excellent clinical results jointly help RainMed to accelerate the commercialization of caIMR In the process of coronary heart disease diagnosis and treatment, IMR evaluation has important clinical significance and has been widely recommended by domestic and foreign guidelines. Data show that 40% of patients with coronary artery disease still suffer from recurrent angina after PCI, partly due to microcirculatory dysfunction. Therefore, guidelines such as "Guidelines for Diagnosis and Management of Chronic Coronary Syndrome", "Chinese Expert Consensus on Diagnosis and Treatment of Coronary Microvascular Diseases (2017)", "Chinese Multidisciplinary Expert Consensus on Diagnosis and Treatment of Microvascular Diseases (2020)" and other guidelines all recommend IMR assessment in patients with coronary heart disease. caIMR of RainMed caIMR of RainMed has made up for the deficiencies of traditional guide wire-derived IMR detection, and offered more practical clinical detection methods to coronary microcirculation. In the past, guide wire-derived IMR measurement requires the use of hyperemic agents and repeated injection of normal saline, which takes a long time to measure IMR and has a high risk and therefore it is only suitable for clinical research. caIMR does not require the pressure guide wire and hyperemic agents. It does not need to change the surgeon's surgical habits. It only takes an average of 5 minutes to measure IMR based on angiograms, blood flow velocity by TIMI frame count, real-time aortic pressure and a specially-designed CFD model. It is safe, efficient and simple, and offers a new opportunity to promote the large-scale clinical application of coronary microcirculation assessment.   As the world's first diagnostic method for coronary microcirculation function in the confirmatory clinical trial stage, RainMed caIMR was successfully approved to enter the green channel of innovative medical devices, bringing sufficient confidence to accelerate the large-scale clinical application of the product.   As of December 2021, RainMed caIMR has successfully completed the clinical enrollment of the confirmatory trial. The study is led by Zhongshan Hospital Affiliated to Fudan University with the top cardiology experts academician Ge Junbo and Professor Huo Yong of Peking University First Hospital as PI. At present, caIMR has achieved excellent clinical research results and has successfully entered the registration clinical stage. caIMR confirmatory clinical research launch ceremony The preferential policies and assistance to high-innovation medical devices given by the state and the confirmatory clinical results that exceeded expectations have brought more confidence to accelerate the commercialization of caIMR. It is believed that the large-scale clinical application of caIMR will surely improve the level of diagnosis and treatment of coronary artery disease and lead coronary artery disease into a new era of precision medicine.    Top SCI journals confirm that caIMR of RainMed has a wide range of clinical indications and excellent clinical application value The global initiative of RainMed caIMR has attracted extensive attention from well-known experts at home and abroad, and has become a hot topic of international clinical research. A number of blockbuster research papers published in SCI journals have made detailed demonstra

Recently, the "Jingxi Talk" hosted by Yiou Health was held in Beijing. The CHS 2023 China Health Industry Innovation List was released at the meeting. After more than three months of collection and se

Privacy Policy

The 7th Annual Meeting of Medical Scientists (2022), the theme event of the Chinese Medical Doctor Association’s only newspaper "MD weekly", was held in Beijing on March 18th. At the meeting, the "Power to drive the industry forward" and the annual "Top 10 Pharmaceutical Innovation Enterprises" were voted and Suzhou RainMed Medical Technology Co., Ltd., Pfizer, AbbVie, ZedLab, etc. won the award. As an innovative medical technology company, RainMed Medical has always been committed to pushing the industry forward. Together with the world's top pharmaceutical companies, we won the annual award issued by the authoritative organization, which is a high recognition and commendation of the achievements of RainMed Medical and has attracted wide attention from all sides.  

Recently, the first animal experiment of a vascular interventional surgery Robot of RainMed Medical- Flash Robot was successfully conducted in Suzhou. In this experiment, Flash Robot of RainMed Medical realized automatic optical positioning puncture, angiography-guided push, rapid functional diagnosis, interventional channel construction, surgical navigation guidance, postoperative evaluation and management, etc. There were no surgical complications such as vasospasm during the whole experiment, and the experiment verified the clinical operability, safety and effectiveness of the vascular interventional surgical robot system. The success of this animal experiment marks a big step forward for RainMed Medical to become the world's leading vascular interventional surgical robot company.

Compared with the traditional guide wire-derived FFR, RainMed’s coronary angiography-derived fractional flow reserve (caFFR) has a high consistency of 95.7%, which is the highest consistency of FFR products in China.

Previously, International top journal in cardiovascular field, Journal of the American College of Cardiology (JACC: Cardiovascular Interventions) published a study by Samsung Medical Center in South Korea and Zhongshan Hospital of Fudan University titled "Functional Coronary Angiography- Derived Index of Microcirculatory Resistance in Patients With ST- Segment Elevation Myocardial Infarction". The article points out that caIMR has significant predictive value for survival status in patients with acute myocardial infarction after PCI, which marks caIMR of RainMed, the world's first epoch-making technology, has solved the shortcomings of traditional microcirculation measurement methods and achieved a leap forward in the diagnosis of microcirculation disorders.

At present, RainMed Medical has successively established strategic cooperative relations with top enterprises such as Ping An Capital, GE Medical China, China Resources Medical Devices, Jointown Medical Devices, Hanxiputai and so on. Through a series of strategic cooperation, RainMed Medical builds a high-end circle of friends in the field of accurate diagnosis and treatment, jointly promotes the capital operation, technology innovation, marketing, channel building, and accelerates the ecological building and strategic implementation of vascular interventional surgery robots to better empower clinicians and benefit the patients with cardiovascular disease at home and abroad.

In recent years, RainMed Medical has continued to establish close scientific research cooperation with dozens of domestic and foreign top medical centers, such as Zhongshan Hospital affiliated to Fudan University, Peking University First Hospital, Peking Hospital, Sungkyunkwan University Samsung Medical Center in South Korea, and continue to publish more than 20 articles in famous SCI journals. Four of the articles were included in top journals such as and , leading the upsurge of clinical research on coronary function.

On December 18th, 2021, RainMed Coronary Physiology Forum was successfully held during the China Cardiovascular Health Conference 2021. Renowned cardiovascular experts from all over the country held a heated discussion on the research progress, clinical significance and application scenarios of caFFR and caIMR, angiography-derived coronary function assessment indicators.

Recently, Ping An Capital and RainMed Medical held a strategic cooperation launch ceremony in Suzhou. Dong Liu, Chairman of Ping An Capital, Yunfei Huo, Chairman of RainMed Medical and Yunlong Huo, co-founder of RainMed Medical participated in the signing ceremony. Lin Wang, senior investment director of Ping An Capital, and Kangjian Liu, vice president and secretary of the board of Directors of RainMed Medical signed a strategic cooperation agreement on behalf of both sides.

Suzhou RainMed Medical Technology Co., Ltd. (hereinafter referred to as "RainMed"), a vascular interventional surgery robot company, announced the completion of nearly $100 million series D financing led by Ping An Capital, the core private equity platform of China Ping An Group. Seresia Asset Management, Lighthouse Canton and other internationally renowned capital followed. This is after the completion of the series C financing of hundreds of millions of yuan led by the well-known institution Jinglin Asset, co-create Weiye and other shareholders, and the company has once again won the support and favor of top institutions.

On October 21st, 2021, Suzhou RainMed Medical Technology Co., Ltd. (hereinafter referred to as "RainMed") announced that its products Coronary Analysis System caFFR (model ASC15) and Disposable Blood Pressure Transducer (model CPT-1500) have obtained the national sales license issued by the local medical device regulatory authority in Serbia, which marks the launch of caFFR in Serbia.

Recently, GE Healthcare China and RainMed Medical successfully signed a strategic cooperation agreement. The two sides will work together to innovate coronary interventional diagnosis and treatment models and procedures, and strive to create more accurate and high-quality integrated precision interventional diagnosis and treatment, and jointly improve the efficiency and level of coronary disease diagnosis and treatment.

Guangming Online invited Prof. Yunlong Huo, co-founder of RainMed Medical, professor and doctoral supervisor of Institute of Mechanobiology, Shanghai Jiao Tong University, to accept an exclusive interview. In the interview, Prof. Huo talked about his original intention and perseverance of returning to China to start his own business. He said, "From the laboratory to the clinic, this is my poem and beyond", "If I believe that what I am doing is right, then I will continue to take root in it and make it to the extreme".

On October 30th, 2021, during the 32nd Great Wall International Congress of Cardiology and Ansian Heart Society Congress 2021, RainMed Satellite Meeting at noon was successfully held. At the meeting, experts and scholars discussed the development of caFFR and caIMR coronary artery detection technology and the clinical application of caFFR. Participants pointed out the importance of coronary microcirculation diagnosis and noted that the effective combination of caFFR and caIMR can significantly improve the macro and micro functional diagnosis of myocardial ischemia.

On October 25th, 2021, Suzhou RainMed Medical Technology Co., Ltd. and Jointown Medical Devices Group Co., Ltd. held the signing ceremony of strategic cooperation agreement in Beijing.

On October 20th, China Resources Pharmaceutical Commercial Group Medical Devices Co.,Ltd. and Suzhou RainMed Medical Technology Co.,Ltd. held the signing ceremony of strategic cooperation agreement in

On October 6th, 2021, RainMed Satellite Conference was successfully held in Rizhao, Shandong province during the 6th Shanghai and Shandong Expert Forum on Cardiovascular Diseases. Renowned experts in

The 15th Qianjiang International Cardiovascular Conference was successfully held in Hangzhou, Zhejiang province on September 25th, 2021.

Recently, some new technical engineers joined RainMed Medical and received systematic training on medical knowledge and products of the company, which injected vitality into RainMed.

On August 31, 2021, Suzhou RainMed Medical Technology Co., Ltd. signed a strategic cooperation agreement with Hanxiputai (Beijing) Hospital Investment Management Co., Ltd.

In coronary artery disease, for patients with moderate stenosis, the diagnosis of coronary vessels only based on angiographic images will be ignored in 1/3 of patients with ischemia, which is easy to

High salary，High commission！ We don't value experience, we vaue ability.

The diagnosis and evaluation of coronary microcirculation has been widely concerned, but only 5% of coronary vessels can be observed by CT, imaging and other imaging methods. The development of caIMR

In a recent paper published in the Journal Of The American College Of Cardiology (JACC), Dr. Joo Myung Lee and his team report on functional coronary angiography-derived Index of microcirculation resi

It has valuable predictive value for INOCA patients, angina pectoris after PCI, acute myocardial infarction, patients with microcirculation disorders after heart transplantation and after TAVI, and ha

The temperature continued to rise in July, and members of the marketing team of RainMed also gathered at the headquarters of the Suzhou company in Jiangsu for mid-year marketing meetings.

On Tuesday, July 20, 2021, technical engineers from RainMed went to Shanghai Zhabei Central Hospital, where they has been in deep cooperation, to provide clinical support for the evaluation and diagno

At present, FFR has been widely recognized as the gold standard in coronary artery diagnosis.

Sharing of precise PCI diagnosis and treatment cases under the clinical guidance of caFFR

At the end of June, we contacted Prof. Qiheng Yao from the Shenzhen Hospital of the University of Hong Kong. Through the interview, Prof. Yao introduced to us the clinical of caFFR.

The director of the department is very satisfied with the contrasting results and the speed of caFFR test. At the same time, two blood vessels can be diagnosed by caFFR, which is much faster than trad

Prof. Dong Huang gave a detailed introduction to the caIMR clinical experiment and explained the FLASH III program for evaluating the microcirculation resistance index of coronary angiography.

At the 15th Oriental Congress of Cardiology(OCC2021), the Satellite Symposium of Suzhou RainMed Medical Technology Co., Ltd. was successfully held

【RainMed】Video recording of the webinar on May 26

On May 7, 2021, during the China Interventional Therapeutics (CIT 2021) Conference, RainMed online Satellite Conference was successfully held . Combined with clinical cases, cardiologists across the c

On April 23-24, 2021, the 24th CCIF Notional Interventional Cardiology Forum was grandly held in Suzhou. More than 23,000 experts from all over the country attended this conference online and offline.

Coronary Physiologic Assessment for Microvascular Disease: Present and Future

RainMed in the 24th China Cardiovascular Intervention Forum,caFFR debut!

In the case of stenosis caused by coronary calcified plaque, caFFR can help doctors accurately plan PCI, which has been unanimously approved by doctors.

caFFR,No pressure guide wire, no need for vasodilators, no additional operations, the detection can be completed at the same time as the angiography, and the accuracy is high, which improves the clini

RainMed Technical Engineer

The University of Hong Kong Shenzhen Hospital with caFFR.

Brand New FlashAngio caFFR System Successfully Installed in Shanghai Sixth People's Hospital!

Flash caFFR II is a prospective, multi-center, blinded, randomized, non-inferior clinical trial of coronary angiography blood flow reserve (caFFR) versus pressure guidewire (FFR) to guide the strategy

happy new year

Resting indexes of coronary physiology——Prof.Huo's speech part.

On November 18th（Beijing time）RainMed participated in the offline medical product display conference held by UMEDWINGS in Shenzhen.

RainMed online webinar Resting indexes of coronary physiology

Dr. Chandan - MBBS 2010 - MR.C.P (Ed) 2015 - Currently working as a fellow in training, Department of Cardiology at the Sarawak Heart Centre, Malaysia since 2018.

Research progress and clinical application of functional assessment in interventional treatment of bifurcation lesions

If you happen to miss RainMed online webinar on September 2nd, and would like to know more about this great event.